Nitin Jain, MD
Internal Medicine · Houston, TXNPI 1659459113
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $217,393 of the $280,791 with a category attached, or 77.4%. It is spread thinly across 30 manufacturers, the largest accounting for just 14.3%. 2025 is the largest year on record at $77,390, 3.2 times the $24,387 reported in 2019. Among internal medicine clinicians in TX with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 239 payments — averaging $1174.86 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$40K
- Astrazeneca UK Limited$37K
- Gilead$36K
- Lilly USA, LLC$33K
- AbbVie$33K
- Hikma Pharmaceuticals USA$31K
- plus $71K from 24 others
Across 168 payments — averaging $196,185 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- AbbVie$25.5M
- Pharmacyclics LLC, An Abbvie Company$1.6M
- Eli Lilly$1.5M
- Takeda Pharmaceuticals U.S.A., Inc.$1.1M
- Genentech, Inc.$1M
- Astrazeneca UK Limited$832K
- plus $1.4M from 10 others
What the payments were for
- Consulting fees$217,39377%
- Speaking & faculty fees$25,3009%
- Travel & lodging$30,87811%
- Food & beverage$7,2203%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 26 | $40,259 |
| Astrazeneca UK Limited | 24 | $37,023 |
| Gilead(2 entities) | 25 | $36,290 |
| Lilly USA, LLC | 14 | $32,959 |
| AbbVie | 30 | $32,742 |
| Hikma Pharmaceuticals USA | 12 | $30,686 |
| Beigene USA, Inc. | 11 | $16,459 |
| Genentech USA, Inc. | 8 | $7,844 |
| Janssen Scientific Affairs, LLC | 3 | $7,715 |
| Genentech, Inc. | 7 | $7,447 |
| Janssen Research & Development, LLC | 4 | $6,518 |
| Pharmacyclics LLC, An Abbvie Company | 4 | $5,217 |
| Adaptive Biotechnologies Corporation | 6 | $4,523 |
| E.r. Squibb & Sons, L.L.C. | 2 | $4,151 |
| Ipsen Biopharmaceuticals, Inc | 1 | $3,915 |
| Beone Medicines USA, Inc. | 3 | $2,670 |
| Beigene, Ltd. | 1 | $1,300 |
| BTG International Inc. | 2 | $1,068 |
| Johnson & Johnson | 33 | $551 |
| Bristol Myers Squibb | 5 | $313 |
| ADC Therapeutics America, Inc. | 2 | $297 |
| Janssen Global Services, LLC | 1 | $273 |
| Rigel Pharmaceuticals, Inc. | 2 | $220 |
| Astellas Pharma US Inc | 2 | $96 |
| Boehringer Ingelheim | 5 | $85 |
| Eli Lilly | 2 | $58 |
| Incyte Corporation | 1 | $58 |
| Medtronic | 1 | $24 |
| Jazz Pharmaceuticals Inc. | 1 | $15 |
| Actelion Pharmaceuticals US, Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$280,791 in reported general payments places this provider in the 95th percentile of 7,675 internal medicine providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| VenclextaVenetoclax | 31 | $189,894 |
| ValacyclovirValacyclovir Hcl | 27 | $1,174 |
| Levofloxacin | 14 | $131 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieVenclexta | $32,742 | $189,89431 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 7,675 internal medicine providers in Texas.
Other internal medicine in Houston
- Hussein TawbiHouston$365K
- Hans LeeHouston$327K
- Tapan KadiaHouston$311K
- Krina PatelHouston$255K
- Nicholas ShortHouston$247K
- Naveen PemmarajuHouston$230K
- Mariana Chavez MacgregorHouston$188K
- Shumei KatoHouston$180K
- Sukhdeep BasraHouston$168K
- Paolo StratiHouston$164K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.